Manuscripts
Showing 1600 manuscripts.
Understanding practices of lactation and infant feeding together with women with HIV: the UPLIFT observational study protocol
Citation
Christiana Smith, Emily Anne Barr, Karen Hampanda, Mark Trumbull, Hulin Wu, Jennifer McKinney, Sarah Buisson, Carly Hoffmann, Ciarra Covin, Angela Hutchinson, K. Rivet Amico, Ifeyinwa V. Asiodu, Elizabeth J. McFarland, Margaret Lampe, Preetam A. Cholli, Olga Varechtchouk, Allahna Esber, Athena P. Kourtis, Lisa Abuogi, UPLIFT (IMPAACT 2046) study team. Understanding practices of lactation and infant feeding together with women with HIV: the UPLIFT observational study protocol. Frontiers in Reproductive Health. 2026 Jul 07; 8. doi: 10.3389/frph.2026.1856899. PMID: 42488399; PMCID: PMC13388547.Year
2026
Journal
Frontiers in Reproductive Health
Study
IMPAACT 2046
Validation of an UHPLC-MS/MS Assay for the Quantification of Isoniazid and Four Major Metabolites in Human Plasma
Citation
David Nerguizian, Brandon Klein, Farah Abdelmawla, Joe Gomez , Peter L Anderson, Lane Bushman, Kristina M Brooks. Validation of an UHPLC-MS/MS Assay for the Quantification of Isoniazid and Four Major Metabolites in Human Plasma. Biomedical Chromatography. 2026 Jul 17; PMID: 42466481; PMCID: PMC13377673.Year
2026
Journal
Biomedical Chromatography
Study
P1078
Maternal and pregnancy outcomes in women offered daily oral preexposure prophylaxis during pregnancy and postpartum
Citation
Benjamin H Chi, Deborah Kacanek, Emily Brown, K Rivet Amico, Sharon Huang, Teacler Nematadzira, Elizea Horne, Clemensia Nakabiito, Sharon K Mambiya, Violet Korutaro, Tichaona Vhembo, Michael Whitton, Benjamin Johnston, Olga Varechtchouk, Hans Spiegel, Peter L Anderson, Lynda Stranix-Chibanda , IMPAACT 2009 protocol team. Maternal and pregnancy outcomes in women offered daily oral preexposure prophylaxis during pregnancy and postpartum. Journal of International AIDS Society. 2026 Jul 28; doi: 10.1097/QAD.0000000000004588. PMID: 42517223; PMCID: PMC13431001.Year
2026
Journal
Journal of International AIDS Society
Study
IMPAACT 2009
Breastmilk transfer and infant exposure to atazanavir/ritonavir in breastfeeding women with HIV: results from IMPAACT 2026
Citation
Emily Anne Barr, Mauricio Pinilla, Jeremiah D Momper, Ahizechukwu C Eke, Lucy Koech, Kristina M Brooks, Victoria Ndyanabangi, Sandra Burchette, Sujith Valiyaparambil, Mark Mirochnik, Alice Stek, Brookie Best, Rachael Jeffrey, Chelsea Krotje, Marije Van Schalkwyk, Renee Browning, David Shapiro, Kathleen M Powis. Breastmilk transfer and infant exposure to atazanavir/ritonavir in breastfeeding women with HIV: results from IMPAACT 2026. Frontiers in Reproductive Health. 2026 Aug 21; doi: doi: 10.3389/frph.2026.1892081. eCollection 2026. PMID: 42666560; PMCID: PMC13523135.Year
2026
Journal
Frontiers in Reproductive Health
Study
IMPAACT 2026
Congenital Infections as Risk Factor For Adverse Birth Outcomes Among HIV-Exposed Neonates in Uganda
Citation
Patience Atuhaire, Mark J Giganti, Flynn McMorrow, Maxensia Owor, Philippa Musoke, Mary Glenn Fowler, Promise Bf Team. Congenital Infections as Risk Factor For Adverse Birth Outcomes Among HIV-Exposed Neonates in Uganda. Journal of the Pediatric Infectious Diseases Society. 2026 Sep 10; doi: 10.1093/jpids/piag090. PMID: 42720400; PMCID: 13641073.Year
2026
Journal
Journal of the Pediatric Infectious Diseases Society
Study
1077BF
Characterizing immune activation in HIV-exposed but uninfected infants in the first year of life
Citation
Isabelle Roseto, Lori Silveira, Kaili Curtis, Jennifer Canniff, Adriana Weinberg, Christiana Smith. Characterizing immune activation in HIV-exposed but uninfected infants in the first year of life. Frontiers in Immunology. 2026 Sep 03; 17:1914801. doi: DOI: 10.3389/fimmu.2026.1914801. PMID: 42755921; PMCID: PMC13582223.Year
2026
Journal
Frontiers in Immunology
Study
P1025
Designing the Study of Glecaprevir/Pibrentasvir Treatment During Pregnancy
Citation
Ravi Jhaveri, Kristina M. Brooks, Vincent Mainella, John Marcinak, Mong-Jen Chen, Katie McCarthy, Camlin Tierney, Zhongli J. Zhang, Bryan Nelson, Pat Flynn, Nathan Furukawa, Ahizechukwu C. Eke, IMPAACT 2041 Protocol Team. Designing the Study of Glecaprevir/Pibrentasvir Treatment During Pregnancy. Open Forum Infectious Diseases. 2026 Aug 28; 13(9). doi: 10.1093/ofid/ofag537. PMID: 42703521; PMCID: PMC13546789.Year
2026
Journal
Open Forum Infectious Diseases
Study
IMPAACT 2041
Pharmacokinetics of Efavirenz in Pregnancy and Postpartum with and without First-line Tuberculosis Drugs: Results from IMPAACT P1026s
Citation
Marije Van Schalkwyk, Jiajia Wang, Adrie Bekker, Eric Decloedt, Gerhard B Theron , Mark F Cotton, Tim R Cressey, Deo Wabwire, Chelsea Stotz, Kevin Knowles, Kathleen George, Renee Browning, Kittipong Rungruengthanakit, Lubbe Wiesner, Edmund V Capparelli, Alice M Stek, Mark Mirochnick, David E Shapiro, Brookie M Best, Ahizechukwu C Eke, IMPAACT P1026s Protocol Team. Pharmacokinetics of Efavirenz in Pregnancy and Postpartum with and without First-line Tuberculosis Drugs: Results from IMPAACT P1026s. Clinical Pharmacokinetics. 2026 Oct 03; doi: doi: 10.1007/s40262-026-01690-w. PMID: 42828638.Year
2026
Journal
Clinical Pharmacokinetics
Study
P1026S
Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, sin
Citation
Carolyn Bolton Moore, Kristin Baltrusaitis, Edmund V Capparelli, Elizabeth D Lowenthal, Dwight E Yin, John H Moye , Christiana Smith, Michael Whitton, Conn M Harrington , Herta Crauwels, Rodica Van Solingen-Ristea, Mark A Marzinke, Barbara Heckman, Andi Ace, Shawn Ward, Kyle Whitson, Jenny Huang, S Y Amy Cheung, Brookie M Best, Ellen Townley, Allison Agwu, Pradthana Ounchanum, Sisinyana Ruth Mathiba, Linda Aurpibul, Violet Korutaro, Gaerolwe Masheto, Faeezah Patel, Evette Moodley, Aditya H Gaur, IMPAACT 2017 Collaborators for the IMPAACT 2017 Team. Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, single-arm trial. Lancet Child and Adolescent Health. 2026 Oct 06; S2352-4642. doi: 10.1016/S2352-4642(26)00221-X. PMID: 42838065.Year
2026
Journal
Lancet Child and Adolescent Health
Study
IMPAACT 2017
Evaluation of Three Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/?NS2/?1313/I1314L, RSV/6120/?NS2/1030s, and RSV/276 in RSV Seronegative Children
Citation
Coleen K. Cunningham, Ruth A. Karron, Elizabeth J. McFarland, Mark J. Giganti, Rachel Ketchum, Charlotte Perlowski, Jennifer Libous, Haley Brozik, Jennifer Oliva, Dwight E. Yin, Patrick Jean-Philippe, Jack Moye Jr., Elizabeth Schappell, Emily Barr, Vivian Rexroad, Benjamin Johnston, Grace Malonga , Mariam Aziz, Tori Rutherford, Heidi Sallee, Jennifer Jao, Robert Frenck, Jaime G. Deville, Emmanuel B. Walter, James Christopher Day, Stephen A. Spector, Andrés Camacho-Gonzalez, Joanna Dobroszycki, Sharon Nachman, Mary E. Paul, James Campbell, Xueqiao Liu, Lijuan Yang, Cindy Luongo, Peter L. Collins, Ursula J. Buchholz, IMPAACT 2021 Study Team. Evaluation of Three Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/?NS2/?1313/I1314L, RSV/6120/?NS2/1030s, and RSV/276 in RSV Seronegative Children. Journal of Infectious Diseases. 2026 Oct 03; jiag489. doi: DOI: 10.1093/infdis/jiag489. PMID: 42828774.Year
2026
Journal
Journal of Infectious Diseases
Study
IMPAACT 2021